As mentioned earlier, pharmacological use of GLP-1 agonists is primarily taken to treat T2D and obesity, and they have impactful effects to achieve in desired results to regulate plasma glucose levels, they also reduce hunger and suppress daily calorie intake
The FDA authorized the emergency use of BNT162b2, which was developed by Pfizer-BioNTech, and mRNA-1273, developed by Moderna
For the patient who likes fewer clinic visits and consistent drug levels, semaglutide is the easier choice
To further explore the pancreatic response to GLP-1, we assessed the response to GLP-1RA treatment in isolated islets from PamKO mice and wildtype littermates
Compounded GLP-1 medications bypass these gatekeeping requirements entirely, allowing immediate access to semaglutide injections through licensed pharmacies without any insurance claim or approval process